Here the induction of FOXP3 degradation in Treg cells provides a potential method that enables transient inhibition of suppressive Treg cells, and thus USP21 is a potential drug target for future anti-cancer immunotherapy (Fig. 8). This evidence concerns the gene USP21 and cancer.